Hear Phathom at three upcoming healthcare investor conferences
Phathom Pharmaceuticals (Nasdaq: PHAT) announced its participation in three investor conferences in May and June 2026: the Craig-Hallum Institutional Investor Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs Global Healthcare Conference. Management will attend these events to participate in one-on-one meetings and fireside chats. The company, focused on GI treatments, will discuss vonoprazan, its first-in-class potassium-competitive acid blocker.
Phathom (NASDAQ: PHAT) director gains shares via options and RSUs
Phathom Pharmaceuticals director Asit Parikh increased his holdings by exercising options for 17,500 shares at $4.95 each and receiving 24,122 Restricted Stock Units (RSUs). These RSUs will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on his continued board service. Following these transactions, Parikh directly holds 52,122 shares and indirectly holds 120,500 shares through a trust.
Director Frank Karbe receives 24,122 RSUs at Phathom (NASDAQ: PHAT) under board compensation plan
Phathom Pharmaceuticals director Frank Karbe was granted 24,122 Restricted Stock Units (RSUs) on May 19, 2026, as part of the company's Non-Employee Director Compensation Program. These RSUs, which convert into common stock upon vesting, are set to vest 100% on the earlier of one year from the grant date or the next annual stockholder meeting, contingent on his continued board service. Following this award, Karbe now directly holds 91,622 shares of Phathom common stock.
Director at Phathom Pharmaceuticals (PHAT) granted 24,122 RSUs
Heidi Fields, a director at Phathom Pharmaceuticals (PHAT), received a grant of 24,122 Restricted Stock Units (RSUs) on May 19, 2026, as part of the company's Non-Employee Director Compensation Program. These RSUs, which have a grant price of $0.00 per share, will vest fully on the earlier of the first anniversary of the grant date or the next annual shareholder meeting, contingent on her continued board service. Following this award, Fields now beneficially holds 54,122 shares of Phathom Pharmaceuticals common stock, reflecting equity compensation rather than a stock purchase.
Phathom Pharmaceuticals (NASDAQ: PHAT) reports 2026 annual meeting vote outcomes
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) announced the voting results from its 2026 Annual Meeting of Stockholders held on May 19, 2026. Stockholders elected three Class I directors for three-year terms, ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026, and gave advisory approval for the compensation of named executive officers. All proposals presented were approved by the stockholders.
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Phathom Pharmaceuticals showcased extensive independent research on vonoprazan, the active ingredient in VOQUEZNA, at Digestive Disease Week (DDW) 2026. The meeting featured 31 vonoprazan-related clinical abstracts, including 28 independent analyses covering various gastrointestinal conditions such as GERD, H. pylori eradication, long-term safety, and post-endoscopic submucosal dissection use. A Phathom-sponsored analysis of heartburn and regurgitation from the Phase 3 pHalcon-NERD-301 trial also received a "Poster of Distinction" designation at the event.
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
Needham analyst Joseph Stringer has reiterated a Buy rating for Phathom Pharmaceuticals (PHAT.US) and maintained a target price of $28. According to TipRanks data, Stringer has a 46.5% success rate and a 23.8% average return over the past year. This rating is based on an independent third-party analysis of financial analysts' recommendations.
Number of shareholders of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT
This article provides details on the number of shareholders for Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), offering insights into its financial data and market performance. It includes a basic overview of Phathom Pharmaceuticals on the Nasdaq Stock Market. The content appears to be a stub or a data-driven report from TradingView, focusing on shareholder numbers as a key metric.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Phathom Pharmaceuticals (NASDAQ:PHAT) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $25.00. Institutional investors hold a significant 99.01% of the shares, with several major funds increasing their stakes. The company recently reported better-than-expected quarterly earnings and revenue that was largely in line with estimates, though its shares were down slightly to $12.16.
Phathom Pharmaceuticals (Nasdaq:PHAT) - Stock Analysis
Phathom Pharmaceuticals (PHAT) is a biopharmaceutical company focused on gastrointestinal disease treatments, with its stock currently trading significantly below its estimated fair value. Analysts forecast strong earnings growth and anticipate the company reaching profitability in 2026. Recent updates highlight FDA approvals for VOQUEZNA in various GERD conditions, along with ongoing clinical trials and strategic financial management to support its long-term market position.
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline
Phathom Pharmaceuticals (PHAT) saw an 11.0% stock increase after reporting a significantly narrowed Q1 2026 net loss of US$30.37 million, down from US$94.32 million year-over-year. The company reaffirmed its 2026 guidance, expecting net revenues between US$320 million and US$345 million, and targeting operating profitability by Q3 and for the full year, excluding stock-based compensation. This progress supports the investment narrative around its product VOQUEZNA, aiming for sustained profitability despite inherent risks tied to a single product.
Phathom Pharmaceuticals (NasdaqGS:PHAT) Stock Forecast & Analyst Predictions
Phathom Pharmaceuticals (NasdaqGS:PHAT) is projected to experience significant growth, with earnings forecast to increase by 57.5% and revenue by 28.4% annually. The company is expected to achieve profitability in 2027, with numerous analyst updates and price target revisions reflecting both optimism for its product VOQUEZNA and concerns regarding financial risks like shareholder dilution and cash runway. Recent developments include FDA approvals, ongoing clinical trials, and strategic management appointments.
Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3
Phathom Pharmaceuticals has provided a financial outlook for 2026, projecting revenues between $320 million and $345 million. The company aims to achieve operating profitability by the third quarter of 2026. This outlook reflects the company's strategic goals and anticipated growth in the coming years.
How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing
Phathom Pharmaceuticals Inc. (PHAT) shows a weak near and mid-term sentiment, but a strong long-term outlook with an exceptional 114.0:1 risk-reward setup. AI models have generated three trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, targeting different risk profiles and holding periods. The analysis highlights key support and resistance levels across various time horizons for PHAT.
147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc.
Hussman Strategic Advisors Inc. recently purchased 147,000 shares of Phathom Pharmaceuticals (NASDAQ:PHAT) valued at approximately $2.44 million, increasing its stake to 0.21%. This comes as Phathom Pharmaceuticals reported Q1 revenue that beat estimates due to strong VOQUEZNA sales, although the company remains unprofitable with a slight EPS miss. Analysts are largely bullish, with a "Moderate Buy" consensus and a $25 price target, and shares rose 7.2% on the news.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX)
This article examines analyst sentiments for three healthcare companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA), and Nanobiotix (NBTX). Phathom Pharmaceuticals received a Strong Buy consensus with significant upside potential, while TELA Bio also garnered a Strong Buy rating. Nanobiotix, however, has a Strong Buy consensus but with a more modest upside, and one analyst maintained a Hold rating.
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call
Phathom Pharmaceuticals reported robust Q1 2026 results, with net revenues doubling year-over-year fueled by strong VOQUEZNA prescription growth and expanded sales force initiatives. Despite short-term revenue being slightly below internal expectations due to seasonality and market access, the company maintained its full-year guidance, emphasizing disciplined spending, a solid cash position, and advancements in its clinical pipeline. Management expects to reach operating profitability later this year, although high gross-to-net discounts and future competition remain potential challenges.
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5% - Should You Buy?
Phathom Pharmaceuticals (NASDAQ:PHAT) saw its stock price rise 7.5% during mid-day trading on Friday, driven by a Q1 revenue beat and narrowed losses for its VOQUEZNA product. Analyst sentiment remains largely positive, with several firms raising price targets and a consensus rating of "Moderate Buy" with a $22.50 target. Despite a slight EPS miss, the improved commercial traction and ongoing analyst support suggest a potentially positive outlook for the company.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2026 Earnings Call Transcript
Phathom Pharmaceuticals reported its Q1 2026 earnings, showcasing a 104% year-over-year revenue growth to $58.3 million, though missing EPS expectations at $-0.37. The company emphasizes its refined strategy focusing on gastroenterologists for VOQUEZNA, aiming for $1 billion in annual revenue in GI and anticipating a future expansion into primary care. Despite competitive landscape considerations, Phathom maintains its full-year 2026 revenue guidance and expects to achieve operating profitability by Q3 2026, driven by strong new-to-brand prescription rates and disciplined expense management.
GERD drug VOQUEZNA gets 3 posters and a May 4 presentation at DDW
Phathom Pharmaceuticals will highlight its GERD drug VOQUEZNA at Digestive Disease Week (DDW) 2026 with three poster presentations and a product theater session on May 4. The company aims to engage with the GI community and share clinical, patient-reported, and real-world data for VOQUEZNA. This engagement is part of Phathom's ongoing commercialization push for the drug, following recent financial updates emphasizing revenue growth and profitability targets.
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
Phathom Pharmaceuticals will participate in the Digestive Disease Week (DDW) 2026 annual meeting from May 2-5 in Chicago, Illinois. The company plans to highlight its drug VOQUEZNA (vonoprazan) through a product theater presentation and an exhibit booth. Phathom will also present clinical and real-world data across three poster presentations, demonstrating its commitment to advancing GERD treatment.
Phathom Pharmaceuticals (PHAT) Loss Compression Challenges Bearish Narratives After Q1 2026 Results
Phathom Pharmaceuticals (PHAT) released its Q1 2026 results, reporting $57.6 million in revenue and a significant reduction in EPS loss to $0.29. The company's net losses have shrunk from $94.3 million to $21.1 million over six quarters, supporting a bullish outlook on its path to profitability within three years. Despite ongoing trailing losses and negative shareholders' equity, analysts maintain a high fair value and price target, fueled by strong revenue growth forecasts and expected margin improvements.
Phathom Pharmaceuticals, Inc. (PHAT) reports Q1 loss, tops revenue estimates
Phathom Pharmaceuticals, Inc. (PHAT) announced a Q1 loss but exceeded revenue estimates. The company reported a net loss of $0.66 per share, which was better than analysts' expectations. Revenue for the quarter came in at $21.9 million, surpassing the estimated $18.57 million.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) reported a Q1 loss of $0.18 per share, missing the Zacks Consensus Estimate of a $0.17 loss, but significantly improved from a $1.07 loss a year ago. The company's revenues reached $58.3 million, topping the Zacks Consensus Estimate by 2.76% and marking a substantial increase from $28.52 million in the prior year. Despite beating revenue estimates, PHAT shares have declined 29% year-to-date, and the stock currently holds a Zacks Rank #3 (Hold).
Phathom Pharmaceuticals reports Q1 2026 revenue $58.3M, narrows net loss to $30.4M
Phathom Pharmaceuticals reported Q1 2026 net revenues of $58.3 million and significantly narrowed its GAAP net loss to $30.4 million from $94.3 million in Q1 2025. The company maintained its full-year 2026 guidance, expecting operating profitability to begin in Q3 2026. Key achievements include increased VOQUEZNA prescription fills, improved insurance coverage, a fully deployed sales force, and progress in its clinical development programs.
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals reported significant revenue growth for Q1 2026, reaching $58.3 million, a 104% increase year-over-year, driven by the commercial success of VOQUEZNA. The company maintained its 2026 financial guidance, anticipating operating profitability starting in Q3 2026 and for the full year, and expects to achieve cash flow positivity in 2027. Despite seasonal fluctuations, VOQUEZNA prescriptions and covered prescriptions showed strong year-over-year growth, and the Phase 2 EoE trial is enrolling ahead of schedule.
Phathom Pharmaceuticals (NASDAQ: PHAT) doubles Q1 2026 revenue, cuts loss
Phathom Pharmaceuticals reported a significant increase in Q1 2026 net product revenue, reaching $58.3 million, more than double the prior year, primarily driven by VOQUEZNA prescriptions. The company also substantially narrowed its operating loss to $15.5 million and improved its non-GAAP adjusted net loss to $14.7 million due to reduced operating expenses. Management reiterated its full-year 2026 guidance, expecting to achieve operating profitability by Q3 2026 and cash flow positivity in 2027.
1.35M VOQUEZNA prescriptions filled; Phathom expects Q3 operating profitability
Phathom Pharmaceuticals (Nasdaq: PHAT) reported a significant increase in Q1 2026 net revenues, up 104% year-over-year to $58.3 million, with approximately 1.35 million total VOQUEZNA prescriptions filled to date. The company maintained its full-year 2026 financial guidance and anticipates achieving operating profitability, excluding stock-based compensation, starting in Q3 2026 and for the full year. Despite a strong revenue performance, the stock declined 12.56% following the news, reflecting a negative market reaction.
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q1 Adjusted Loss $0.18 per Share, vs. FactSet Est of $-0.21
Phathom Pharmaceuticals, Inc. (PHAT) reported an adjusted loss of $0.18 per share for Q1, which is better than FactSet's estimated loss of $0.21 per share. The company's stock shows a 5-day change of +6.38% and a Q1 2026 earnings call was held on April 30, 2026. Phathom Pharmaceuticals focuses on developing and commercializing treatments for gastrointestinal diseases with its primary product candidate, VOQUEZNA.
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
Phathom Pharmaceuticals will participate in the Digestive Disease Week (DDW) 2026 annual meeting from May 2-5 in Chicago, Illinois. The company plans to highlight its drug VOQUEZNA (vonoprazan), a potassium-competitive acid blocker for GERD, through a product theater presentation and an exhibit booth. Phathom will also present clinical and real-world data on VOQUEZNA across three poster presentations, demonstrating its commitment to advancing GERD treatment.
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals reported significant revenue growth for the first quarter of 2026, with net revenues reaching $58.3 million, a 104% increase year-over-year, driven by the commercial success of VOQUEZNA. The company also announced a strategic shift to gastroenterology, maintained its full-year 2026 financial guidance, and expects to achieve operating profitability starting in Q3 2026. Phathom is well-positioned for future growth, aiming for $1 billion in annual revenue from gastroenterology prescriptions, supported by disciplined cost management and a strong cash position.
Phathom Pharmaceuticals to present VOQUEZNA clinical data at DDW2026 event
Phathom Pharmaceuticals will present updated clinical data on its VOQUEZNA (vonoprazan) therapy at a live product theater presentation during Digestive Disease Week (DDW2026) on May 4th. The session aims to inform healthcare professionals and stakeholders about the efficacy and safety profile of VOQUEZNA for gastric acid-related conditions. This presentation is part of Phathom's ongoing efforts to engage professionals and leverage educational sessions to promote its therapeutic offerings.
Phathom says FDA confirmed Voqueza exclusivity through May 2032
Phathom Pharmaceuticals announced that the FDA has confirmed its New Chemical Entity (NCE) exclusivity for Voquenza (vonoprazan) tablets until May 2032. This regulatory protection covers both 10 mg and 20 mg dosages and was granted following the approval of Phathom's New Drug Application for the treatment of erosive esophagitis. The exclusivity provides an additional two years of market protection beyond what was initially expected, preventing the FDA from approving generic versions during this period.
Phathom says FDA confirmed Voqueza exclusivity through May 2032
Phathom Pharmaceuticals announced that the FDA has confirmed its market exclusivity for Voqueza (vonoprazan) through May 2032. This extends the regulatory protection for the acid blocker, first approved in late 2023, by an additional two years. The news follows a favorable decision from the US Patent and Trademark Office's Patent Trial and Appeal Board regarding a patent for vonoprazan.
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet
Wall Street analysts are optimistic about Phathom Pharmaceuticals (PHAT), with an average price target suggesting an 87.21% upside potential. The latest ratings indicate a consensus "Strong Buy" recommendation for the stock. Investors should consider these analyst insights before making investment decisions.
HC Wainwright & Co. Maintains Phathom Pharmaceuticals (PHAT) Buy Recommendation
This article states that HC Wainwright & Co. has reiterated its 'Buy' rating for Phathom Pharmaceuticals (PHAT). It also mentions a price target of $28.00, suggesting a potential upside for the stock.
Phathom Pharmaceuticals (PHAT) Projected to Post Earnings on Thursday
Phathom Pharmaceuticals (PHAT) is slated to release its Q1 2026 earnings before market open on Thursday, April 30th. Analysts anticipate the company will report earnings of ($0.17) per share and revenue of $58.619 million. The company's shares recently opened at $12.16, and analysts currently have a "Moderate Buy" consensus rating with a target price of $22.50.
(PHAT) and the Role of Price-Sensitive Allocations
This article provides a quantitative analysis of Phathom Pharmaceuticals Inc. (NASDAQ: PHAT), highlighting a weak near-term sentiment but strong mid and long-term outlook. It details AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report suggests elevated downside risk in the near term but positive sentiment prevailing thus far.
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
Phathom Pharmaceuticals will report its first quarter 2026 financial results and provide a business update via a live webcast on Thursday, April 30, 2026, at 8:00 am EDT. The biopharmaceutical company focuses on developing and commercializing treatments for gastrointestinal diseases, including its product VOQUEZNA for GERD and H. pylori infection. A recording of the webcast will be available for 90 days on the company's investor relations website.
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6.8% - Time to Sell?
Phathom Pharmaceuticals (NASDAQ:PHAT) saw its shares drop 6.8% on Tuesday, trading at approximately $12.55 with lower-than-average volume. Despite the dip, analysts maintain a "Moderate Buy" consensus rating with an average target price of $22.50, and several firms have recently raised their price targets. The company, which has a market cap of $1.03 billion, beat earnings estimates for the quarter, largely due to its lead asset vonoprazan for GI disorders, and institutional ownership stands at a high 99.01%.
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
Phathom Pharmaceuticals (Nasdaq: PHAT) is scheduled to report its first-quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. The company will host a live webcast at 8:00 am EDT on that day to discuss its performance and recent developments, focusing on its advancements in treating gastrointestinal diseases. The article also notes that PHAT is currently RSI overbought, suggesting potential short-term consolidation.
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
Phathom Pharmaceuticals (Nasdaq: PHAT) is scheduled to report its first-quarter 2026 financial results and provide a business update via a live webcast on Thursday, April 30, 2026, at 8:00 am EDT. The company specializes in developing and commercializing treatments for gastrointestinal diseases, including vonoprazan, marketed as VOQUEZNA for GERD and H. pylori infection. A recording of the webcast will be available for 90 days on their investor relations website.
Phathom to pair Q1 results with a business update in April 30 webcast
Phathom Pharmaceuticals (Nasdaq: PHAT) announced it will report its first quarter 2026 financial results and provide a business update via a live webcast on Thursday, April 30, 2026, at 8:00 am EDT. The company, which commercializes vonoprazan as VOQUEZNA products for GERD and H. pylori, will make a recording of the webcast available for 90 days. This follows a consistent pattern of pre-announcing earnings dates, which has previously correlated with positive stock price movements.
Phathom Pharmaceuticals to Report First Quarter 2026
Phathom Pharmaceuticals announced it will host a live webcast on Thursday, April 30, 2026, at 8:00 am EDT to report its first quarter 2026 financial results and provide a business update. The company is focused on developing and commercializing novel treatments for gastrointestinal diseases, specifically vonoprazan (VOQUEZNA®) for GERD and H. pylori infection. The webcast will be accessible on the company's investor relations website.
Phathom surges 125% after FDA grants petition on Voquezna exclusivity
Phathom Pharmaceuticals saw its stock surge by 125% after the FDA granted its Citizen Petition, affirming Voquezna's new chemical entity (NCE) exclusivity. This ruling prevents generic versions from entering the market until at least 2029, a significant win following initial concerns about Voquezna's exclusivity length for both erosive and non-erosive gastroesophageal reflux disease indications. The decision also invalidated a paragraph IV certification for a generic version, strengthening Phathom's market position.
Responsive Playbooks and the PHAT Inflection
This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT), indicating strong sentiment across all horizons and an exceptional 114.3:1 risk-reward setup. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, supported by multi-timeframe signal analysis. The analysis suggests an overweight bias for PHAT, targeting a 28.6% gain with minimal risk.
[ARS] Phathom Pharmaceuticals, Inc. SEC Filing
This article announces an ARS SEC filing by Phathom Pharmaceuticals, Inc. (PHAT) on April 7, 2026, which is available as a PDF document. It also provides an overview of the company's stock performance rankings, latest news, and other recent SEC filings, including a DEF 14A and Form 4 insider trading activity. Key financial data like market cap, float, industry, and sector are also listed.
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals announced its participation in upcoming investor conferences in April, including the Raymond James 2026 Biotech Innovation Symposium and the 25th Annual Needham Virtual Healthcare Conference. Management plans to engage in one-on-one meetings at both events and present a fireside chat at the Needham Conference. The company, focused on GI diseases, will discuss its commercialization of vonoprazan (VOQUEZNA®) for various conditions.
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals announced its management team will attend two investor conferences in April 2026: the Raymond James 2026 Biotech Innovation Symposium and the 25th Annual Needham Virtual Healthcare Conference. The company specializes in treatments for gastrointestinal diseases, particularly commercializing vonoprazan-based products for GERD and H. pylori infection. Webcasts of the events will be available on the company's investor relations website.
Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT
Hennion & Walsh Asset Management Inc. recently purchased 114,981 shares of Phathom Pharmaceuticals (NASDAQ:PHAT) during the fourth quarter, representing a new position valued at approximately $1.91 million. This acquisition contributes to the significant institutional ownership of 99.01% for Phathom Pharmaceuticals. The company recently reported better-than-expected Q4 earnings and revenue, and analysts maintain a "Moderate Buy" rating with an average price target of $22.50.
